Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.17M Sell
42,544
-2,357
-5% -$62.6K 0.01% 731
2026
Q1
$1.2M Buy
44,901
+140
+0.3% +$4.2K 0.01% 663
2025
Q4
$1.38M Buy
44,761
+11,265
+34% +$351K 0.01% 616
2025
Q3
$1.03M Sell
33,496
-330
-1% -$8.04K 0.01% 688
2025
Q2
$699K Buy
33,826
+2,147
+7% +$44.1K ﹤0.01% 794
2025
Q1
$620K Buy
31,679
+5,529
+21% +$116K ﹤0.01% 772
2024
Q4
$546K Sell
26,150
-7,112
-21% -$156K ﹤0.01% 801
2024
Q3
$811K Sell
33,262
-222
-0.7% -$5.93K ﹤0.01% 683
2024
Q2
$841K Sell
33,484
-2,264
-6% -$64.2K 0.01% 660
2024
Q1
$1.07M Buy
35,748
+1,853
+5% +$54.4K 0.01% 602
2023
Q4
$1.08M Sell
33,895
-6,966
-17% -$219K 0.01% 556
2023
Q3
$1.44M Buy
+40,861
New +$1.56M 0.01% 448
2023
Q1
Sell
-9,677
Closed -$410K 1055
2022
Q4
$410K Buy
9,677
+770
+9% +$31.7K ﹤0.01% 753
2022
Q3
$286K Sell
8,907
-2,385
-21% -$83.7K ﹤0.01% 827
2022
Q2
$367K Sell
11,292
-800
-7% -$25.9K ﹤0.01% 763
2022
Q1
$437K Sell
12,092
-3,347
-22% -$115K ﹤0.01% 767
2021
Q4
$611K Buy
15,439
+322
+2% +$13.4K ﹤0.01% 701
2021
Q3
$661K Buy
15,117
+1,544
+11% +$69.3K ﹤0.01% 651
2021
Q2
$554K Buy
+13,573
New +$524K ﹤0.01% 620

Other funds holding GMAB

Davenport & Co's GMAB Position: Q2 2026 in Review

Davenport & Co reduced its Genmab (GMAB) stake by 5.2% in Q2 2026, selling an estimated $62.6K and leaving 42,544 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #731.

Davenport & Co first reported a position in GMAB in Q2 2021 and has held it in 19 quarters since. The position peaked at $1.44M in Q3 2023. 41 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Davenport & Co held 42,544 shares of Genmab worth $1.17M as of Q2 2026.
  • Davenport & Co sold 2,357 Genmab shares in Q2 2026, an estimated $62.6K.
  • Genmab made up 0.01% of Davenport & Co's portfolio in Q2 2026, its #731 holding.
  • Davenport & Co first reported a position in Genmab in Q2 2021 and has held it in 19 quarters since.
  • Davenport & Co's Genmab position peaked at $1.44M in Q3 2023.
  • 41 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.